This work is based on a master thesis in applied clinical science at The Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway. The content is concealed until 2018.
Sources of financial and material support:The expenses were covered by the Norwegian Advisory Unit on Headache Gravdahl
Abstract:Objective: Headache is a controversial indication for treatment of pituitary adenoma. We sought to study the possible relationship between pituitary adenomas and headache along with the symptomatic effects of treatment.Methods: 201 patients with pituitary adenoma underwent structured telephone interviews addressing current and prior headache complaints. Clinical variables and headache history were retrieved from medical records. Headache prevalence among patients was compared to a regional population-based cohort.Results: Headache suffering prior to the pituitary adenoma diagnosis was higher than in the general population (p<0.001). At follow-up, overall prevalence was lower (p<0.001), but chronic headache was more prevalent (p= 0.001) than in the general population. With the exception of family history, no associations between headache and clinical or radiological variables were identified. 77% of headache sufferers reported improvement and5 % reported worsening while 11 % reported new headaches at follow-up. Operated patients with non-functional adenoma more often reported improvement (85%) than non-operated patients (58%) (p=0.042).
Conclusion:In a cohort with both treated and untreated patients with pituitary adenoma headache prevalence is low compared to the general population. We found no link between clinical or radiological variables and headache. Even though a higher proportion of operated patients report symptomatic relief, the majority of non-treated patients also improved. We believe that the rather unpredictable dynamics of headache over time and the lack of predictive and modifiable tumor related variables associated with headache or relief we believe this weakens headache as a sole indication for pituitary adenoma treatment.